The current spectrum of infection in cancer patients with chemotherapy related neutropenia

Infection

Volumn 42, Issue 1, 2014, Pages 5-13

  Nesher, Lior ^a   Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Infection; Malignancy; Neutropenia

Indexed keywords

CARBAPENEM DERIVATIVE; CHLORHEXIDINE; COTRIMOXAZOLE; CYTARABINE; DAPTOMYCIN; FLUCONAZOLE; LINEZOLID; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANAEROBIC INFECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CANCER CHEMOTHERAPY; CANCER PATIENT; CATHETER INFECTION; CATHETER REMOVAL; CELLULAR IMMUNITY; CELLULITIS; CHEMOTHERAPY ASSOCIATED NEUTROPENIA; ENTEROCOLITIS; FEBRILE NEUTROPENIA; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; HUMORAL IMMUNITY; INDUCTION CHEMOTHERAPY; INFECTION; INFECTION CONTROL; INTESTINE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL INFECTIONS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; FUNGI; HUMANS; MYCOSES; NEOPLASMS;

EID: 84898540675     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0525-9     Document Type: Review

References (62)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-37. (Pubitemid 38063629)
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.
4. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control. 2003;10(5):396-403. (Pubitemid 37296067)
5. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794-810.
6. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012;10(11):1412-45.
7. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32(7):841-50.
8. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45(2):228-33. (Pubitemid 47041015)
9. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agent. 2007;30(Suppl 1):S51-9.
10. Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56(5):711-7.
11. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13(11):870-7. (Pubitemid 41502246)
12. Sandoval C, Sinaki B, Weiss R, et al. Urinary tract infections in pediatric oncology patients with fever and neutropenia. Pediatr Hematol Oncol. 2012;29(1):68-72.
13. Cecinati V, Brescia L, Tagliaferri L, Giordano P, Esposito S. Catheter-related infections in pediatric patients with cancer. Eur J Clin Microbiol Infect Dis. 2012;31(11):2869-77.
14. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003;37(8):1144-5. (Pubitemid 37323675)
15. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother. 2010;65(9):1955-8.
16. Wisplinghoff H, Seifert H. Wenzel RP. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States: Edmond MB; 2003.
17. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol. 2012;52(2):203-8.
18. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29(3):490-4. (Pubitemid 29439940)
19. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine (Baltimore). 1986;65(4):218-25. (Pubitemid 16049280)
20. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474-9.
21. Samonis G, Vardakas KZ, Maraki S, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer. 2013;21(9):2521-2526.
22. Cortés JA, Cuervo S, Gómez CA, Bermúdez D, Martínez T, Arroyo P. Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. Biomedica. 2013;33(1):70-7.
23. Kang CI, Song JH, Chung DR, et al. Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer. 2012;20(10):2371-8.
24. Ram R, Farbman L, Leibovici L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents. 2012;40(2):123-6.
25. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49(1):1-45.
26. Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis. 2010;51(7):801-3.
27. Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG. Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol. 2012;88(5):422-30.
28. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398-402. (Pubitemid 38747480)
29. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106(8):1815-20.
30. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755-71.
31. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.
32. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14(6):1201-7.
33. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18(1):25-31. (Pubitemid 24025915)
34. Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol. 2006;44(1):160-5. (Pubitemid 43100595)
35. Rolston KV, Jiang Y, Matar M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transpl. 2007;39(9):567-8. (Pubitemid 46629593)
36. Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613-619.
37. Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67(3):266-9.
38. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533-41.
39. Patel G, Bonomo RA. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol. 2013;4:48.
40. Pillai DR, McGeer A, Low DE. New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: emerging resistance. CMAJ. 2011;183(1):59-64.
41. Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012;91(8):1299-304.
42. Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Non-fermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005;51(3):215-8. (Pubitemid 40568767)
43. Rolston KV, Tarrand JJ. Pseudomonas aeruginosa - still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis. 1999;29(2):463-4. (Pubitemid 29380232)
44. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother. 2004;48(1):329-32. (Pubitemid 38040217)
45. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104(1):205-12. (Pubitemid 40847770)
46. Demiraslan H, Sevim M, Pala Ç, et al. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients. Int J Hematol. 2013;97(3):414-20.
47. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001;41(1-2):71-8. (Pubitemid 33001462)
48. Sood P, Seth T, Kapil A, et al. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc. 2012;110(7):439-44.
49. El-Sharif A, Elkhatib WF, Ashour HM. Nosocomial infections in leukemic and solid-tumor cancer patients: distribution, outcome and microbial spectrum of anaerobes. Future Microbiol. 2012;7(12):1423-9.
50. Chen CY, Cheng A, Huang SY, et al. Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia. PLoS One. 2013;8(4):e60624.
51. Brook I, Frazier EH. Aerobic and anaerobic infection associated with malignancy. Support Care Cancer. 1998;6(2):125-31. (Pubitemid 28110536)
52. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091-100.
53. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22(8):470-4. (Pubitemid 37100593)
54. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6(9):e24198.
55. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents. 2006;27(Suppl 1):3-6. (Pubitemid 44218692)
56. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493-9.
57. Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453-64.
58. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818-28.
59. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950-2. (Pubitemid 38252550)
60. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010;60(5):331-7.
61. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989 to 2006. Clin Infect Dis. 2006;43(12):1580-4. (Pubitemid 44901901)
62. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983;99(6):773-6. (Pubitemid 14248403)